A team of MUSC Hollings Cancer Center researchers has discovered one way in which triple-negative breast cancer (TNBC) cells become resistant to immunotherapy and have tested a two-pronged treatment ...

Personalized Therapy Biosimulation Study Identifies Homologous Recombination Deficiency in Cancer Patients Beyond BRCA Status BARCELONA, Spain, September 16, 2024--(BUSINESS WIRE)--Cellworks ...

Researchers have discovered new insights into tumor-induced B cell changes in blood and bone marrow of triple negative breast cancer patients. The findings show two distinct patterns of B cell ...

In 2021, the FDA blasted Merck for using a premature endpoint to pursue a Keytruda approval in early-stage triple-negative ...

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that data for the novel, potential ...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ ... a phase 2 study that enrolled 43 patients with stage I-III triple-negative breast cancer (TNBC). Patients in the study underwent short-term ...

Scientists at Huntsman Cancer Institute at the University of Utah (the U), the National Cancer Institute-designated cancer center for the Mountain West, have made a significant breakthrough in ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug ...

Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...

Researchers examine the association between patient-derived xenograft with recurrence and survival rates in triple negative ...

Hollings Cancer Center researchers have identified one reason why triple-negative breast cancer becomes resistant to ...